Euretina Congress

A post hoc analysis of the phase 2 FILLY study demonstrated that patients who received multiple intravitreal injections of pegcetacoplan had a lower rate of progression from nascent geographic atrophy to GA as compared with sham.

Nine-month data from a phase 1/2 clinical trial of AAV-RPGR gene therapy for X-linked retinitis pigmentosa showed clinically meaningful improvement in retinal sensitivity and vision-guided mobility.

A post hoc analysis of the ARIES study showed a correlation between presence of intraretinal fluid and poorer vision, while a stable, limited amount of subretinal fluid may be beneficial.

At the virtual Euretina meeting, Anat Loewenstein, MD, discusses digitally enhanced visualization in vitreoretinal surgery using the Beyeonics digital visualization system.

At the virtual Euretina meeting, Ramin Tadayoni, MD, PhD, presents the results of the phase 2 study of OCS-01, the first topical treatment for diabetic macular edema.

A local approach for the treatment of unilateral or asymmetric uveitis and systemic therapy for bilateral uveitis are effective guidelines, but they can be interchangeable for certain patients, according to a speaker.

At the virtual Euretina congress, Francesco Bandello, MD, speaks about faricimab, a drug that combines anti-VEGF and Ang-2-blocking properties.

Injection in the subretinal space, currently performed or investigated for several cell-based and gene therapy procedures, could soon become more precise and safer with the help of robotics.

The consumption of energy drinks leads to acute, reversible changes in retinal vascular density parameters, according to a study presented at the virtual Euretina meeting.

At the Euretina congress, Tunde Peto, MD, PhD, discusses the potential benefits but also the legal, ethical and technical challenges of artificial intelligence applied to the management of patients with diabetic retinopathy.